TSC22D1 (TSC22 domain family member 1) is a multifunctional transcriptional regulator with tissue-specific and context-dependent roles in cell physiology and disease. Primary functions include regulating cell death, apoptosis, and transcriptional processes 1. TSC22D1 exhibits isoform-dependent activities: short isoforms function as tumor suppressors promoting apoptosis and cell-cycle exit 2, while long isoforms paradoxically promote cell proliferation 2. Mechanistically, TSC22D1 operates through multiple pathways: it inhibits insulin secretion in pancreatic beta cells by interacting with FoxO1 and regulating glucose-responsive processes 3, modulates WNK kinase signaling in kidney distal convoluted tubules to regulate sodium reabsorption 4, and mediates LSEC-macrophage communication via the TWEAK/FN14 pathway 1. TSC22D1 localizes to nucleus, cytoplasm, and mitochondria depending on isoform and cellular context 5. Clinically, elevated TSC22D1 expression predicts tamoxifen resistance in breast cancer patients 6, while TSC22D1 inhibition reduces non-alcoholic fatty liver disease progression to fibrosis 1. These findings establish TSC22D1 as a multivalent regulator with potential therapeutic implications in metabolic diseases, liver fibrosis, and cancer resistance.